It seems we can’t find what you’re looking for. Perhaps searching can help.

About Divya Chandradhara
Divya Chandradhara is the CEO of BioAgile Therapeutics Pvt. Ltd. A biochemist by education, she has several years of experience in the clinical and pre-clinical research industry. Before joining BioAgile Therapeutics, Divya was associated with Advinus Therapeutics, a TATA group company, handling business for domestic and international markets. She is well known in the industry, with collaborations across multinational companies and academic institutions, and holds several internationally cited publications in clinical and pre-clinical studies. Divya reviews BioAgile Therapeutics’ clinical research and regulatory content before publication.
Articles reviewed by Divya Chandradhara
- How to choose a CRO in India: a sponsor’s evaluation framework
- Informed consent in clinical trials in India: what the NDCT Rules require
- Serious adverse event reporting in Indian clinical trials: who reports, to whom and by when
- ICH GCP guidelines: the 11 principles of ICH E6(R3) and what changed for sponsors
- CTRI registration: how a clinical trial is registered with the Clinical Trials Registry of India
- New Drugs and Clinical Trials Rules, 2019: what sponsors have to do
- Phases of clinical trials: what Phase I to Phase IV involve and how India regulates each
- Clinical study report writing: what ICH E3 requires, section by section